Core momentum solid, lithium sampling phase—capex not yet productive
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Core business beat seasonal expectation and overcame macro headwinds; lithium remains unproven (samples only, yields improving). No full-year guidance given; acknowledged base effects. ₹1,400 Cr FY27 capex plan reaffirmed.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Exide delivered a strong Q1 with 17.7% revenue growth and 27.9% PAT growth, driven by broad-based core business momentum across auto OEM, inverters, and solar—offsetting input cost and currency headwinds through calibrated pricing and operational efficiency. However, the quarter was seasonally favorable (peak inverter summer, early monsoon effect absent vs. prior year), and H2 will face high base comparisons. Lithium-ion capacity building is on track (₹4,902 Cr invested, samples commenced) but remains 5–7 years from material earnings contribution, creating a capex-to-earnings drag. Valuation and upside depend on lithium commercialization execution and core business sustainability amid tightening auto production comparables.
₹5528.4 Cr
Revenue · +17.7% YoY₹351.3 Cr
Reported PAT · +27.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Standalone revenue growth 17.6% YoY
METDelivered ₹5,528.4 Cr, +17.7% YoY
EBITDA ₹655 Cr, +19.5% YoY, 12.4% margin
METCore margin expansion 20 bps YoY despite cost headwinds
All major businesses double-digit growth
METVolume growth in 4W OEM 21%, 2W OEM 20%, 4W replacement 10%, solar 12–14%
Margin expansion 70 bps sequential
METSequential margin leverage confirmed; pricing 4–6% + cost control offset input headwinds
Lithium revenue contribution to commence FY27 shortly
OVERSTATEDSamples just started; commercial production timeline vague; still 25–30% utilization target
Earnings quality
What changed since the last call
Core business momentum intact post-GST
UpgradeQ1 delivered 17.7% revenue growth on broad 2W/4W/solar/inverter strength; auto OEM now at 25% 3Q consecutive vs. low base FY26
Lithium capex plan unchanged
NeutralBoard reaffirmed ₹1,400 Cr investment for FY27; ₹100 Cr deployed in July; no upgrade or cut to ₹7,000 Cr phase 1–2 framework
Lithium timeline clarity reduced
DowngradeSampling commenced but only at pilot scale; 25–30% utilization target for FY27 is 1/4 of installed 6 GWh capacity; commercial traction still speculative
Geopolitical raw-material risk escalated
DowngradeChinese export controls on raw materials effective November; no embargo yet but added procurement friction; localization target 50–60% in 2–3 years (not immediate)
Hyundai/Kia co-investment delayed
WithdrawnAcknowledged delays; no longer expected FY27; customization line will not launch this calendar year
The Q&A
Analysts pressed on lithium margins, OEM names, full-year guidance, and subsidy amounts; MD held disciplined line on 'too early to comment,' avoided competitive name-calling, and declined to forecast rupee revenue for lithium. No evasions on core business fundamentals. Strong pushback on pricing power vs. Chinese imports—MD acknowledged VAT dynamics but argued demand pull was strong.
Volume vs. pricing split — Vibhav Zutshi, JPMorgan
AnsweredVolume double-digit across most businesses (4W replacement 10%, 4W OEM 21%, 2W OEM 20%, solar 12–14%). Price benefit 4–6% YoY. No new contract wins, business as usual.
Full-year guidance — Vibhav Zutshi, JPMorgan
AnsweredCannot give FY guidance. H1 auto OEM base was very low; post-GST boom from Q3 FY26 onward, high base effect in H2. Passenger vehicles 1.2M→1.4M production levels. Q1 seasonally strong (inverter season). Last year early monsoon hurt inverter demand Q1.
Lithium yields — Vibhav Zutshi, JPMorgan
PartialYields improving. Complex startup, process benchmarking ongoing. Real yield visible only at 3-shift full operation. Sample level hard to test full-scale yield. Technology partners helping (NMC and LFP sides).
Lithium volume commitments — Vibhav Zutshi, JPMorgan
AnsweredStarting with 2 lines (1 NMC, 1 LFP). Can fairly quickly load if yields improve. Demand not an issue; 2W market exists (imported cells today). 3W, telecom, stationary—markets exist, just switching to Indian cells.
PLI strategy — Mukesh Saraf, Avendus Spark
DodgedNot supposed to tell strategy yet. Good signal from government. We are a serious player studying fine prints. Set up 6 GWh without PLI support in phase 1.
Lithium cell pricing vs. Chinese imports — Mukesh Saraf, Avendus Spark
PartialToo early to comment on margins. Chinese export VAT reduced 9%→6%, reverting Jan 1. Chinese EV factories loaded; battery makers fully utilized. Overcapacity of last year now absorbed by domestic Chinese demand. These drivers should work in our favor.
Inverter business mix — Mukesh Saraf, Avendus Spark
Answered15–25% range depending on season.
Import duty trajectory — Aditya Jhawar, Investec Capital
AnsweredCell import duty currently 5%. Need 2–3 more serious players to reach 15–18 GWh local capacity. Then government will likely implement approved cell manufacturers list (like solar). Have had conversations; depends on whether OEMs willing to accept higher EV prices or cut production.
2W battery OEM engagement — Aditya Jhawar, Investec Capital
AnsweredTalking to all major OEMs (legacy and new). About 3 OEMs covering ~80% of EV volume. All 3 in homologation process. Will not get 100% volume initially, be another supplier. These customers cover 80–85% of Indian EV market share.
4W battery strategy — Aditya Jhawar, Investec Capital
Answered2 LFP lines: Line 1 for 3W/telecom/stationary. Line 4 (under commissioning) for 4W OEMs. Now seeing major interest from 4W OEMs. Talking to at least 1–2 major 4W OEMs. Will need Line 4 commissioned by end of FY27. No 100% volume, another supplier.
Core business price increases — Vijay Kumar Pandey, Axis Capital
AnsweredQ1 price correction 4–6% across categories. Q2 no decision yet, closely monitoring. Dynamic approach as before, stepping 2%, 1%, 2% as input costs warrant.
Lithium revenue potential — Vijay Kumar Pandey, Axis Capital
PartialVery difficult to say in rupees (depends on commodity prices). 6 GWh capacity, provision for 12 GWh. Put a number around gigawatt hours and that should be revenue depending on commodity prices.
Lithium subsidies — Shubham, Investec Capital
DodgedNot in public domain yet. Will apply for incentives after official production start declaration. Public disclosure will follow if applicable.
Sodium-ion chemistry — Shubham, Investec Capital
AnsweredNot at this moment. India must learn lithium first. Zero knowledge in India on lithium. Must master this first, then think of other chemistries.
Lead-acid capex and capacity — Pramod Amthe, InCred Capital
AnsweredAllocate ~₹500 Cr annually to core lead-acid (manufacturing tech, automation, capacity). Debottlenecking approach, not full lines. 5 SLI factories, all have brownfield expansion headroom. Aware of 2.5–3 year replacement cycle from current auto production.
BESS cell strategy — Pramod Amthe, InCred Capital
AnsweredLFP format, large format cells 300+ Ah for BESS. Line 4 (second LFP line) next target. Lower gestation than OEMs (project-based, tender-based, no homologation required).
Lithium utilization reaffirmation — Raghunandhan, Nuvama Research
AnsweredYes, stand by it. Line 3 LFP will utilize faster than 2W line due to shorter time-to-market. Yield will be good enough to reach that utilization.
FY27 lithium investment — Raghunandhan, Nuvama Research
AnsweredBoard approved ₹1,400 Cr for this fiscal year. Will review if needed. ₹100 Cr deployed in July. Rest in upcoming months.
₹7,000 Cr total capex plan — Raghunandhan, Nuvama Research
AnsweredMight change +/– due to currency rates (imports). Phase 2 won't require as much (land/utilities already done). Might exceed plan due to changed business case. Will fund from operational cash flows.
Hyundai/Kia co-investment line — Raghunandhan, Nuvama Research
PartialDiscussion ongoing in parallel. Won't come this calendar year or fiscal year. Co-investment, customization line. Delays being faced.
FY26 lithium assembly revenue — Raghunandhan, Nuvama Research
AnsweredVery less, ₹100–200 Cr. Not profitable (low value add with imported cells; not long-term viable without own cell).
Lithium OEM approvals — Ashvath Rajan, Arihant Capital Markets
PartialSupplied samples to OEMs. Homologation process time-consuming. Will then get back for serial production (normal process). Mainly 2W and 3W; not started 4W yet.
Lithium utilization trajectory — Ashvath Rajan, Arihant Capital Markets
Answered2W, 3W, telecom, stationary: 2 lines fully operational out of 4. Even with partial utilization of these 2 lines, reach 25–30% total factory utilization. Depends on yield how quickly reach capacity.
Raw material sourcing with Chinese subsidy removal — Animesh Jain, Dalal & Broach Broking
AnsweredRaw material still from China (samples only at this stage). Talking to Indian companies with plans to invest; doing pilots. Takes 3–5 years for India to develop own sourcing.
Chinese raw material embargo — Animesh Jain, Dalal & Broach Broking
PartialNo embargo yet. Export control announcement doesn't cover raw material yet (effective November). No embargo, only additional approvals (export control). From Nov, will need to monitor, possibly keep higher inventory. Operational topic.
Phase 2 chemistry direction — Animesh Jain, Dalal & Broach Broking
AnsweredPhase 2 mostly LFP, most likely.
Competitor names — Divyansh Thakur, Finterest Capital
DodgedWon't name others. That's analyst job to find out. If you get information, happy to know what others doing. Will see physical progress.
Electrolyte sourcing — Meet Katrodiya, Niveshaay
AnsweredCurrently importing (tech partners' established supply chain). Not using untested suppliers. Talking to large Indian manufacturer (listed company). Doing running pilot. First component to be localized likely electrolyte (large company, serious, has technology).
Localization timeline — Meet Katrodiya, Niveshaay
AnsweredTarget 50–60% BOM localized in 2–3 years. Talking to multiple companies for all components (electrolyte, positives, negatives). If reach 50–60% in 2–3 years, will be very happy.
Chinese tech transfer interference — Munindra Upadhyay, Elara Capital
AnsweredLucky to have completed tech tie-ups and factory setup before embargoes. Licensed 4–5 products. Invested in pilot line; 100+ R&D engineers in Bangalore. Pilot plant by end of calendar year. Main line came first (vs. others who did reverse, now facing machinery embargo delays). In case future no tech licenses, at least 4–5 products will continue; parallelly develop own know-how on pilot line.
Future tech alternatives — Munindra Upadhyay, Elara Capital
AnsweredYes, Korean options available technologically. Only thing they are costlier than Chinese.
Guidance
No full-year FY27 revenue guidance given
LowMD declined, citing visibility challenges and high H2 base effects post-GST boom Q3–Q4 FY26
Core lead-acid business: mid-to-high-double-digit momentum in Q1, seasonal factors Q2–Q4
MediumQ1 17.7% achieved; H2 automotive OEM comparables high, replacement market supports longer term
Lithium-ion: 25–30% plant utilization FY27, samples → commercial ramp H2
MediumConditional on yield improvements, customer approvals. 2 lines (1 NMC, 1 LFP) to drive early ramp
No explicit margin guidance for lithium given (too early)
LowMD said margins uncertain; dependent on competitive pricing, volumes, yields, commodity costs
Core business: margin maintained via calibrated pricing (4–6% Q1) + cost control
HighEBITDA margin 12.4% Q1; Q2 price decisions pending based on cost evolution; cost excellence program ongoing
Lithium: ₹1,400 Cr approved for FY27; ₹100 Cr deployed July; rest in upcoming months
HighTotal phase 1–2 capex ~₹7,000 Cr (±currency adjustment); phase 2 lighter than phase 1 (shared utilities)
Core lead-acid: ~₹500 Cr annual allocation (debottlenecking, automation, brownfield)
High5 SLI factories with headroom for expansion; no major new-line capex planned
Risks the call surfaced
Lithium commercialization delay
HighSamples only at quarter-end; yields improving but unproven at scale; 2–3 major OEMs in homologation (lengthy process). Commercial revenue may slip beyond FY27.
Lithium capex ROI drag
High₹4,902 Cr cumulative invested; ₹1,400 Cr FY27 approved. PAT only ₹351 Cr FY27. Payback depends on reaching 50–60%+ utilization within 3–5 years.
Geopolitical raw-material supply
MediumChinese export controls on raw materials effective November 2026. Currently 100% import; no buffer. Localization target 50–60% takes 2–3 years. Interim inventory costs may compress margins.
Lithium cell pricing competition
MediumChinese cell manufacturers fully loaded (domestic demand high post Middle East disruptions); may not dump prices. But if capacity becomes available, price war risk high. VAT rebate reversal Jan 27 unknown. Exide early-stage, yields low, pricing power limited.
Core automotive OEM base effect
MediumH1 FY26 auto OEM base was very low (pre-GST rationalization). Q1 FY27 saw 25% growth on that low base and peak season tailwind. H2 FY27 will face high comparables (Q3–Q4 FY26 boomed post-GST). Sequential growth likely to moderate significantly.
Input cost & currency volatility
LowLead LME range-bound in USD, but Rupee depreciation puts pressure. Q1 took 4–6% price correction. Further depreciation or input cost spikes may compress margins if pricing lags.
Management
Score 7/10. Clear on what's accomplished (Q1 numbers, lithium milestones, capex deployment); appropriately cautious on forward guidance (no FY revenue forecast). Disciplined on competitive disclosures (refuses to name competitors). Occasionally evasive on margins, subsidy amounts, and specific customer names (homologation sensitivity). Strong on core business (17.7% revenue, broad-based growth, margin expansion despite headwinds). Lithium on track (4 lines operational, samples commenced, ₹1,400 Cr FY27 approved, 100+ R&D engineers). No material miss vs. prior guidance. Track record B-grade: core delivery strong, lithium still speculative.
1 · Q2 FY27 (Sept 2026)
First 2W OEM lithium battery serial production delivery; yield data from commercial ramp
2 · H2 FY27 (Oct 2026–Mar 2027)
4W OEM line 4 commissioning; 3W aftermarket retrofitment ramp (70% of market opportunity)
3 · Jan 2027
Chinese cell export VAT rebate expires; competitive pressure on lithium cell pricing may ease
Valuation and upside depend on lithium commercialization execution and core business sustainability amid tightening auto production comparables.
Exide starts FY27 strong: consolidated PAT ₹351 Cr, up ~28% YoY on margin expansion
PAT +27.94% YoY · revenue +17.75% · margins expanding
₹5,528.38 Cr
+17.75% YoY
₹351.3 Cr
+27.94% YoY
6.32%
+0.5pp YoY
₹4.12
Exide Industries opened FY27 with a broad-based beat on its own guidance. Consolidated revenue rose ~17.7% YoY to ₹5,528 Cr and net profit climbed ~27.9% YoY to ₹351 Cr (EPS ₹4.12), with profit outpacing revenue — the hallmark of margin expansion rather than volume alone. Net margin widened to ~6.4% from 5.8% a year ago. The standalone print tells the same story (revenue ₹5,305 Cr, +17.6%; PAT ₹407 Cr, +27.1%), so there is no divergence between the two bases. Management's Q4 concall had guided to only high-single to early-double-digit growth in the core lead-acid business; the actual ~18% topline comfortably clears that bar, aided by GST 2.0 affordability tailwinds and double-digit growth across every major vertical.
Q1 FY-2027 vs prior quarters
The margin bridge is the real story. Despite genuine cost headwinds — West Asia-driven input-cost volatility and rupee depreciation against the USD lifting import-linked costs — calibrated price hikes plus cost-excellence and supply-chain gains lifted standalone EBITDA margin to 12.4% (+20 bps YoY, +70 bps QoQ). This directly confirms the prior-call promise to 'protect margins through calibrated price hikes and strict cost controls.' The sequential jump (PAT +62% QoQ vs Q4's ₹217 Cr) is flattered by seasonality — Q1 is peak summer demand for inverters, solar and automotive batteries — so YoY, not QoQ, is the honest read.
The stock went into the print at ₹444.4, up 13.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Balance sheet zero-debt — consolidated EPS ₹4.12 (standalone ₹4.79)
Management projects high single-digit to early double-digit growth for the core lead-acid business, driven by robust domestic demand across key verticals. The company will actively mitigate significant commodity cost pressures through continued calibrated price hikes and strict internal cost controls to protect margins
— This quarter: beat
Growth was led by Automotive OEM (25%+ YoY for a third straight quarter), Reserve Power (20%+), double-digit 2W/4W replacement, and a return to growth in exports (20%+ on a low base). On the new-energy front, the company delivered exactly what it flagged last quarter: Exide Energy Solutions dispatched its first NMC cylindrical cell samples during Q1 and its LFP prismatic line began sample supplies, with all four Bengaluru gigafactory lines installed and utilities operational; a further ₹100 Cr equity infusion in July took cumulative EESL investment to ₹4,902 Cr, against the ₹1,400 Cr FY27 capex plan. Revenue from the plant is guided to begin during FY27. No published street consensus for the quarter surfaced, and management offers no formal quantitative guidance beyond directional commentary; on both counts the print reads at least in-line-to-ahead of a low-double-digit expectation.
W1
Bengaluru gigafactory revenue: management guides commencement during FY27 — watch for first EESL cell revenue and narrowing of its ~₹3 Cr quarterly loss
W2
Margin durability: 12.4% EBITDA margin held via price hikes against rupee/West-Asia cost pressure — verify sustainability if lead/FX worsen
W3
Core volume momentum: whether Auto OEM 25%+ and 20%+ replacement/export growth persist as the GST 2.0 demand tailwind matures
Clean digital filing, unambiguous headers. Consolidated PBT includes ₹0.56 Cr share of associates; PAT ₹351.30 Cr total, of which ₹350.47 Cr to owners and ₹0.83 Cr to NCI. No exceptional item in Q1 FY27 or year-ago Q1 FY26 (both clean) — the labour-code exceptional item sits only in the FY26 full-year column, so YoY needs no adjustment. EESL (li-ion) is a consolidated subsidiary carrying a small net loss (~₹3.34 Cr for one unit).
Strong Core, Lithium Capex Drag — the ₹7,000 Crore Question
Revenue and profit both surged on broad-based momentum, but management sidestepped full-year guidance. The quarter was seasonally favorable, and the real tension sits in lithium: ₹4,902 crore invested so far, still sampling, and 5–7 years from breakeven.
Exide delivered a strong headline: ₹5,528 crore revenue (+17.7% YoY) and ₹351 crore PAT (+27.9% YoY), with EBITDA margin expanding 20 basis points to 12.4% despite raw material and currency headwinds. Broad-based growth across auto OEM (+25%), 2W/4W replacements, solar (record ₹400+ crore), and inverters drove the beat. But management declined to raise full-year guidance. The call reveals why: Q1 benefited from seasonal factors (summer inverter peak, monsoon timing), H2 comparables are punishing, and the real story is ₹4,902 crore already invested in lithium-ion, with another ₹1,400 crore approved for FY27 — all pre-revenue. This is a company running two engines at radically different stages of maturity.
₹5,528 Cr
+17.7% YoY
₹351 Cr
+27.9% YoY
12.4%
+20 bps YoY
₹4,902 Cr
~14x FY27 PAT
What the quarter really was
The core lead-acid business — auto OEM, replacements, inverters, solar — is humming. Broad-based volume growth (auto OEM +21% volume, 2W OEM +20%, 4W replacement +10%, solar +12–14%) combined with calibrated pricing (4–6% YoY) to drive revenue. EBITDA margin expanded 20 basis points despite elevated lead costs and rupee weakness, signaling cost discipline. This is textbook execution in a mature, competitive space.
But three factors made Q1 look better than the underlying trend:
Summer inverter season peaked (inverters 15–25% of revenue, seasonally strong in Q1)
Monsoon timing differed vs. prior year (early monsoon last year suppressed inverter demand; absent Q1 this year)
Auto OEM base was depressed in prior-year H1 (pre-GST rationalization), making +25% easier
Management flagged all three on the call and explicitly warned that H2 FY26 saw the post-GST boom (Q3–Q4), creating high comparables for the second half of FY27. Do not expect +25% auto OEM growth to continue sequentially.
Lithium: on the roadmap, not yet in the earnings
Exide has invested ₹4,902 crore across four production lines (NMC cylindrical, LFP prismatic for 2W/3W, and additional capacity for 4W and stationary). As of quarter-end, samples have commenced. Management targets 25–30% plant utilization in FY27 and full commercialization ramp in the second half.
This timeline is achievable but not yet proven. Yields are improving, but the MD acknowledged that real yield visibility comes only at full 3-shift operation, not sample scale. Customer homologation is ongoing; no serial production volume commitments yet. The 2W OEM engagement covers 3 major players representing ~80% of the EV market; the company expects to be 'another supplier,' not sole source. Raw material supply remains 100% import (Chinese); localization of BOM to 50–60% will take 2–3 years.
Yields are improving, but the real yield will be visible when you run the plant at 3-shift operation. At sample level, it's very difficult to really test the full yield.
Management's claims — what holds up
Standalone revenue growth 17.6% YoY
SupportedDelivered ₹5,528.4 Cr, +17.7% YoY
EBITDA ₹655 Cr, +19.5% YoY; margin 12.4%
SupportedConfirmed; margin expanded 20 bps despite cost/FX headwinds
All major businesses double-digit growth
Supported4W OEM +21%, 2W OEM +20%, 4W replacement +10%, solar +12–14%
Lithium revenue contribution to commence FY27
OverstatedSamples started; commercial production still pending customer approvals; 25–30% utilization target = 1/4 of installed 6 GWh capacity
Margin expansion through pricing + cost control
Supported4–6% pricing + operational efficiency offset input headwinds; EBITDA margin +20 bps YoY
What changed on this call
Core business momentum intact post-GST
Lithium capex plan reaffirmed (₹1,400 Cr FY27)
Lithium timeline clarity reduced (samples only, yields improving but unproven)
Hyundai/Kia co-investment delayed (no FY27 or calendar-year launch)
Geopolitical raw-material risk escalated (Chinese export controls Nov 2026)
The bull-bear ledger
Core business momentum solid (17.7% revenue, +27.9% PAT on broad-based growth)
Margin expansion (20 bps EBITDA) despite cost headwinds via pricing + cost control
Auto OEM 3Q consecutive growth at +25%; replacement cycle supports longer-term demand
Solar at record ₹400+ Cr quarterly; inverters strong
Debt-free; generates cash to fund lithium capex
Lithium on track technically (4 lines operational, 100+ R&D engineers, multiple tech partnerships)
2W/3W EV market growing fast; demand > supply; no domestic competition yet
Lithium still in sample phase; no commercial revenue FY27
Capex ROI drag visible: ₹4,902 Cr invested, PAT only ₹351 Cr; payback 5–7 years away
H2 FY27 will face high auto OEM comparables (post-GST boom Q3–Q4 FY26)
Lithium pricing power uncertain; competing with loaded Chinese capacity
Geopolitical risk: Chinese export controls on raw materials from Nov 2026
Hyundai/Kia co-investment delayed; removes one potential revenue source
Yields improving but unproven at scale; customer approvals pending
Risks, ranked by how much they should concern a holder
Lithium capex ROI and execution timeline
High₹4,902 Cr cumulative investment vs. ₹351 Cr FY27 PAT; ₹1,400 Cr FY27 capex. Payback depends on scaling to 70–80%+ utilization within 3–5 years and sustaining margin against Chinese competitors. If execution slips or pricing erodes, the capex becomes return-destroying.
Lithium sample-to-commercial transition
HighSamples only at quarter-end. Yields improving but unproven at full-scale 3-shift operation. Customer homologation is time-consuming. Serial production volume commitments not yet secured. Timeline risk to FY27 utilization target and revenue ramp in H2.
H2 FY27 auto OEM growth compression
MediumQ1 saw +25% growth on a low prior-year base and seasonal inverter peak. H2 comparables are high (post-GST boom Q3–Q4 FY26). Sequential growth likely to decelerate to single digits, impacting overall FY27 headline growth narrative.
Geopolitical raw-material supply disruption
MediumChinese export controls on raw materials effective November 2026. Currently 100% reliant on Chinese imports (samples only); no localization yet. If applied, could add inventory costs, supply delays, or price spikes. Localization target 50–60% BOM takes 2–3 years.
Lithium cell pricing competition
MediumEarly-stage yields, limited pricing power. Chinese cell makers fully loaded now (domestic EV demand high), but once overcapacity clears or new players enter, price war risk rises. VAT rebate reversal (Jan 2027) may ease import pressure, but no guarantee.
Core auto OEM cyclicality
Low-MediumPassenger vehicle production at 1.4M run-rate is healthy but capped by supply chains. Replacement cycle (2.5–3 years) supports medium-term demand, but OEM growth dependent on new vehicle sales momentum.
How the street is positioned
The market's reaction was muted: day 1 −0.64%, day 3 +1.25%. After an initial dip, a modest recovery — neither a strong conviction buy nor a confident sell. The stock is now at ₹467, which is −2.45% from its all-time high of ₹478.75 but +62.66% off its 52-week low of ₹287.1. RSI of 69.5 is neutral, suggesting room for upside if sentiment improves.
Ownership tells a quieter story. Foreign investors trimmed 62 basis points to 10.30% (from 10.92% in the prior quarter), a subtle signal of caution. Domestic institutional investors added 42 basis points to 19.13%, offsetting the FII reduction. Promoters remain steady at 45.99%. The FII trim — during a quarter of strong headline growth — suggests skepticism about the lithium capex ROI and/or valuation at peak enthusiasm for EV exposure.
Volume trend is increasing, indicating continued retail and tactical interest, but the mix of strong growth + muted price action + FII trimming suggests the street is pricing in the capex drag and waiting for concrete proof of lithium commercialization.
The honest read: the debate
The honest read: Exide is executing well on the core and appears to be executing competently on lithium (4 lines operational, samples out, R&D backed, multiple partnerships). But this is a steady execution story, not a step-change quarter. The reported growth is real, but Q1 was seasonally favorable; H2 will be harder. Lithium is on the roadmap and de-risked technically, but commercialization is still 6–12 months away, and material earnings contribution is 3–5 years away. For investors at ₹467, you are pricing in lithium success and 70–80% utilization by FY28–29. The street's muted reaction (FII trim, day-1 dip) signals that bar is increasingly priced in, leaving room for disappointment. The debate is no longer "will lithium work," but "when, and at what margin."
What to watch next
1 · Q2 auto OEM growth (sequential trend)
Will the sequential deceleration from +25% be as sharp as feared? Core business momentum is the near-term narrative until lithium ramps.
2 · 2W OEM lithium serial production delivery (H2 FY27, from Sept 2026)
First volume sales, customer names, and yield metrics are the lynchpin for FY27 utilization target. Monitor homologation progress and ramp trajectory.
3 · 4W line commissioning (end FY27)
Line 4 is critical for 4W OEM market entry and scaling. Delay cascades risk into FY28.
4 · Chinese export control impact (Nov 2026 onwards)
Does raw-material supply tighten? Does it trigger inventory builds or price spikes? Watch for operational friction in Q3 commentary.
5 · Lithium pricing strategy clarity
MD dodged on the call. Expect disclosure in Q2 or at investor meetings once samples reach OEM testing. Pricing vs. Chinese imports is the single most important variable for ROI.
The single number to track
Core PAT (ex-lithium losses/capex write-downs). Watch whether FY27 core PAT sustains at ₹350+ crore, adjusted for seasonal factors. If sequential growth decelerates below low-single-digit levels in H2, the core thesis weakens, and lithium becomes the only upside — a higher-risk situation. Lithium contribution will remain near-zero through FY27; the first meaningful lithium earnings impact (even if breakeven-level) will be a narrative inflection point.
Exide delivered a solid Q1 — broad-based growth, margin expansion, and disciplined capex execution. But the quarter was seasonally favorable, and the street's muted reaction (FII trim, day-1 dip, RSI neutral) signals lithium execution risk is front-of-mind. This is a steady-state story: the core is reliable, lithium is on track technically, but the earnings inflection is still 18–24 months away. For near-term traders, the H2 base effect is a headwind. For long-term investors, the question is whether Exide can commercialize lithium before the capex burden becomes unbearable.
Verdict: Hold until concrete proof of commercial scale (customer names, volume commitments, yield metrics) emerges 6–12 months out. The core justifies the current stock; lithium is the option value.